# US 2026/0116848 A1 · Synthesis of an Intermediate and Its Use for the Preparation of GLP-1R/GIPR Agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0116848 A1
- Document ID: US20260116848A1
- Status: Published application
- Kind: A1
- Application number: 19/287,728
- Filed: 2025-07-31
- Published: 2026-04-30
- Earliest claimed: 2024-07-31
- Assignees: Carmot Therapeutics Inc.; Hoffmann-La Roche Inc.
- Applicants: Carmot Therapeutics Inc.; Hoffmann-La Roche Inc.
- Inventors: Shyam Krishnan; Raphael Bigler; Pascal Stephan Engl; Carl Florian Falk; Alec Fettes; Michael Kammerer; Christian Steffen Mössner; Pascal Jarno Schmidt; Helene Wolleb; Martina Niess; Philipp Stefan Weber
- Web page: https://patentgrep.com/patent/US20260116848A1

## CPC

- C07C 253/30: by reactions not involving the formation of cyano groups
- B01J 31/2282: {Unsaturated compounds used as ligands}
- B01J 31/2295: {Cyclic compounds, e.g. cyclopentadienyls}
- B01J 31/2409: {with more than one complexing phosphine-P atom}
- C07C 255/57: containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
- C07K 1/042: {characterised by the nature of the carrier}
- C07K 1/20: Partition-, reverse-phase or hydrophobic interaction chromatography
- C07K 14/605: Glucagons
- B01J 2231/4205: C-C cross-coupling, e.g. metal catalyzed or Friedel-Crafts type
- B01J 2531/004: Ligands
- B01J 2531/0205: Bi- or polynuclear complexes, i.e. comprising two or more metal coordination centres, without metal-metal bonds, e.g. Cp(Lx)Zr-imidazole-Zr(Lx)Cp
- B01J 2531/824: Palladium
- B01J 2531/842: Iron
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- B01J: CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to processes for the synthesis of 2-(3-cyano-5-fluorophenyl)-2-methylpropanoic acid and its use as intermediate in the preparation of GLP-1R/GIPR agonists. The invention also relates to a process of preparing a GLP-1R/GIPR agonist.

## Claims

### Claim 1

A process of preparing 2-(3-cyano-5-fluorophenyl)-2-methylpropanoic acid (formula (I)):
comprising
a) reacting 3-bromo-5-fluorobenzonitrile (formula (II)):
with an isobutyrate source in the presence of a palladium cross coupling catalyst to afford an ester of formula (III)
wherein R is C1-4-alkyl, and
b) hydrolyzing the ester of formula (III) to afford 2-(3-cyano-5-fluorophenyl)-2-methylpropanoic acid (formula (I)).

### Claim 2 (depends on 1)

The process of claim 1, wherein the palladium cross coupling catalyst is a Pd-trialkylphosphine complex catalyst.

### Claim 3 (depends on 2)

The process of claim 2, wherein step a) comprises generating the palladium cross coupling catalyst in situ from a Pd precursor and a trialkylphosphine.

### Claim 4 (depends on 1)

The process of claim 1, wherein the isobutyrate source is a C1-4-alkyl isobutyrate or a silyl ketene acetal.

### Claim 5 (depends on 1)

The process of claim 1, wherein the isobutyrate source is methyl isobutyrate or methyl trimethylsilyl dimethylketene acetal.

### Claim 6 (depends on 1)

The process of claim 1, wherein the isobutyrate source is methyl isobutyrate and the reacting takes place in the presence of a strong base.

### Claim 7 (depends on 6)

The process of claim 6, wherein the strong base is a lithium dialkylamide, and wherein the process comprises preparing the lithium dialkylamide in situ from an alkyl lithium compound and a dialkylamine.

### Claim 8 (depends on 6)

The process of claim 6, wherein the reacting in the presence of a strong base takes place in a non-polar organic solvent at a reaction temperature between −10° C. and 30° C.

### Claim 9 (depends on 4)

The process of claim 4, wherein the reacting of the palladium cross coupling catalyst with the silyl ketene acetal takes place in the presence of a Zn compound as co-activator.

### Claim 10 (depends on 9)

The process of claim 9, wherein the silyl ketene acetal is an alkyl trialkylsilyl dialkylketene acetal.

### Claim 11 (depends on 9)

The process of claim 9, wherein step a) takes place in a polar organic solvent at a reaction temperature between 40° C. and 100° C.

### Claim 12 (depends on 1)

The process of claim 1, wherein step b) comprises hydrolyzing the ester of formula (III) with an alkali hydroxide.

### Claim 13 (depends on 12)

The process of claim 12, wherein the alkali hydroxide is lithium hydroxide.

### Claim 14 (depends on 12)

The process of claim 12, wherein step b) takes place in the presence of a non-polar organic solvent at a reaction temperature between 0° C. and 100° C.

### Claim 15 (depends on 1)

The process of claim 1, wherein step b) is carried out with lithium iodide.

### Claim 16 (depends on 1)

2-(3-cyano-5-fluorophenyl)-2-methylpropanoic acid (formula (I)) produced according to the process of claim 1 for use in a method of preparing a compound of formula (VII), or a pharmaceutically acceptable salt thereof:
(VII)
[SEQ ID NO: 1]
X-β-Ala2-Glu3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-
Tyr10-Ser11-Ile12-Aib13-Leu14-Asp15-Lys16-Ile17-
Ala18-Gln19-Lys20(AEEAc-AEEAc-γ-Glu-19-
carboxynonadecanoyl)-Ala21-Phe22-Val23-Gln24-
Trp25-Leu26-Ile27-Ala28-Gly29-Gly30-Pro31-Ser32-
Ser33-Gly34-Ala35-Pro36-Pro37-Pro38-Ser39-NH2,
wherein X is
and
AEEAc is 2-(2-(2-aminoethoxy) ethoxy) acetic acid.

### Claim 17

A process for preparing a compound of formula (VII), or a pharmaceutically acceptable salt thereof:
(VII)
[SEQ ID NO: 1]
X-β-Ala2-Glu3-Gly4-Thr5-Phe6-Thr7-Ser8-Asp9-Tyr10-
Ser11-Ile12-Aib13-Leu14-Asp15-Lys16-Ile17-Ala18-Gln19-
Lys20(AEEAc-AEEAc-γ-Glu-19-carboxynonadecanoyl)-
Ala21-Phe22-Val23-Gln24-Trp25-Leu26-Ile27-Ala28-Gly29-
Gly30-Pro31-Ser32-Ser33-Gly34-Ala35-Pro36-Pro37-Pro38-
Ser39-NH2,
wherein X is
and
AEEAc is 2-(2-(2-aminoethoxy) ethoxy) acetic acid,
comprising:
a) reacting 2-(3-cyano-5-fluorophenyl)-2-methylpropanoic acid (formula (I)) with the resin-bound peptide:
under amide bond-forming conditions.

### Claim 18 (depends on 17)

The process of claim 17, further comprising
b) globally deprotecting and cleaving the compound of formula (VII) from the resin using an acid,
c) precipitating the compound of formula (VII) or salt thereof,
d) purifying the compound of formula (VII) or salt thereof, and
e) isolating the compound of formula (VII) or salt thereof.

### Claim at position 19

19-22. (canceled)

### Claim 23 (depends on 17)

The process of claim 17, wherein the solid phase synthesis comprises sequentially coupling each of the following to the resin or peptide intermediate bound thereto:
(1) Fmoc-L-Ser(O′Bu)-OH,
(2) Fmoc-L-Pro-OH,
(3) Fmoc-L-Pro-OH,
(4) Fmoc-L-Pro-OH,
(5) Fmoc-L-Ala-OH,
(6) Fmoc-Gly-OH,
(7) Fmoc-L-Ser(O′Bu)-OH,
(8) Fmoc-L-Ser(O′Bu)-OH,
(9) Fmoc-L-Pro-OH,
(10) Fmoc-Gly-Gly-OH,
(11) Fmoc-L-Ala-OH,
(12) Fmoc-L-Ile-OH,
(13) Fmoc-L-Leu-OH,
(14) Fmoc-L-Trp (Boc)-OH,
(15) Fmoc-L-Gln(Trt)-OH,
(16) Fmoc-L-Val-OH,
(17) Fmoc-L-Phe-OH,
(18) Fmoc-L-Ala-OH,
(19) ivDde-L-Lys(Fmoc)-OH,
(20) Fmoc-AEEA-OH,
(21) Fmoc-AEEA-OH,
(22) Fmoc-L-Glu-O′Bu,
(23) 20-(tert-butoxy)-20-oxoicosanoic acid, followed by deprotection of ivDde with 3% v/v hydrazine monohydrate/DMF,
(24) Fmoc-L-Gln(Trt)-OH,
(25) Fmoc-L-Ala-OH,
(26) Fmoc-L-Ile-OH,
(27) Fmoc-L-Lys(Boc)-OH,
(28) Fmoc-L-Asp(O′Bu)-OH,
(29) Fmoc-L-Leu-OH,
(30) Fmoc-Aib-OH,
(31) Fmoc-L-Ile-OH,
(32) Fmoc-L-Ser(O′Bu)-OH,
(33) Fmoc-L-Tyr(O′Bu)-OH,
(34) Fmoc-L-Asp(O′Bu)-OH,
(35) Fmoc-L-Ser(O′Bu)-OH,
(36) Fmoc-L-Thr(O′Bu)-OH,
(37) Fmoc-L-Phe-OH,
(38) Fmoc-L-Thr(O′Bu)-OH,
(39) Fmoc-L-Gly-OH,
(40) Fmoc-L-Glu (O′Bu)-OH,
(41) Fmoc-β-Ala-OH, and
(42) 2-(3-cyano-5-fluorophenyl)-2-methylpropanoic acid.

### Claim at position 21

24-33. (canceled)

### Claim 34 (depends on 17)

The process of claim 17, wherein the pharmaceutically acceptable salt of the compound of formula (VII) is an ammonium, potassium, sodium, acetate, chloride, or phosphate salt.
